3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
5
Urothelial Cancer
1
Urinary Bladder Neoplasms
1
Prostate Cancer Patients
1
Prostate Cancer Metastatic
1
Postoperative Cognitive Complications
1
Pharmacokinetics of MDV3100
1
Pain
1
Lung Neoplasms
1
Liposarcoma
1
Gastrointestinal Stromal Tumors
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
3
tislelizumab
1
spartalizumab
1
milademetan
1
enzalutamide
1
devimistat
1
dehydroftorafur
1
Tablets
1
Specimen Handling
1
Solutions
1
Rogaratinib
1
Pemetrexed
1
Midazolam
1
Magnetic Resonance Spectroscopy
1
Letrozole
1
IFL protocol
1
Hydroxychloroquine
1
Gemcitabine
1
Fulvestrant
1
Fluorouracil
1
Cetuximab
1
Carboplatin
1
BID protein, human
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
Midazolam
×
Genitourinary
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled